147 related articles for article (PubMed ID: 26421912)
1. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study.
Mørch LS; Kjaer SK; Keiding N; Løkkegaard E; Lidegaard Ø
Int J Cancer; 2016 Mar; 138(6):1506-15. PubMed ID: 26421912
[TBL] [Abstract][Full Text] [Related]
2. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
[TBL] [Abstract][Full Text] [Related]
3. The influence of hormone therapies on colon and rectal cancer.
Mørch LS; Lidegaard Ø; Keiding N; Løkkegaard E; Kjær SK
Eur J Epidemiol; 2016 May; 31(5):481-9. PubMed ID: 26758900
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
[TBL] [Abstract][Full Text] [Related]
5. Hormone therapy and ovarian borderline tumors: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
[TBL] [Abstract][Full Text] [Related]
6. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
7. Tibolone and risk of gynecological hormone sensitive cancer.
Løkkegaard ECL; Mørch LS
Int J Cancer; 2018 Jun; 142(12):2435-2440. PubMed ID: 29349823
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
9. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study.
Løkkegaard E; Nielsen LH; Keiding N
Stroke; 2017 Aug; 48(8):2266-2269. PubMed ID: 28626058
[TBL] [Abstract][Full Text] [Related]
10. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
11. Continuous combined hormone replacement therapy and risk of endometrial cancer.
Hill DA; Weiss NS; Beresford SA; Voigt LF; Daling JR; Stanford JL; Self S
Am J Obstet Gynecol; 2000 Dec; 183(6):1456-61. PubMed ID: 11120510
[TBL] [Abstract][Full Text] [Related]
12. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy and risk of myocardial infarction: a national register study.
Løkkegaard E; Andreasen AH; Jacobsen RK; Nielsen LH; Agger C; Lidegaard Ø
Eur Heart J; 2008 Nov; 29(21):2660-8. PubMed ID: 18826989
[TBL] [Abstract][Full Text] [Related]
14. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck AR; Park Y; Brinton LA
Int J Cancer; 2013 Jan; 132(2):417-26. PubMed ID: 22553145
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997.
Pukkala E; Tulenheimo-Silfvast A; Leminen A
Cancer Causes Control; 2001 Feb; 12(2):111-5. PubMed ID: 11246839
[TBL] [Abstract][Full Text] [Related]
16. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study.
Jaakkola S; Lyytinen HK; Dyba T; Ylikorkala O; Pukkala E
Int J Cancer; 2011 Apr; 128(7):1644-51. PubMed ID: 21280035
[TBL] [Abstract][Full Text] [Related]
17. Trends in endometrial cancer incidence rates in the United States, 1999-2006.
Duong LM; Wilson RJ; Ajani UA; Singh SD; Eheman CR
J Womens Health (Larchmt); 2011 Aug; 20(8):1157-63. PubMed ID: 21682550
[TBL] [Abstract][Full Text] [Related]
18. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK.
de Vries CS; Bromley SE; Thomas H; Farmer RD
Drug Saf; 2005; 28(3):241-9. PubMed ID: 15733028
[TBL] [Abstract][Full Text] [Related]
19. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
[TBL] [Abstract][Full Text] [Related]
20. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group.
Brinton LA; Hoover RN
Obstet Gynecol; 1993 Feb; 81(2):265-71. PubMed ID: 8380913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
